<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70674">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140541</url>
  </required_header>
  <id_info>
    <org_study_id>R05812</org_study_id>
    <nct_id>NCT02140541</nct_id>
  </id_info>
  <brief_title>The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils</brief_title>
  <official_title>The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research in Real-Life Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Research in Real-Life Ltd</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the relationship between blood eosinophil counts, asthma exacerbations and
      patient asthma control using a large primary care based research database
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sputum eosinophil levels have been shown to predict asthma exacerbation and inhaled
      corticosteroid (ICS) responsivenesss. Managing asthma based on sputum eosinophils leads to
      fewer exacerbations than management adhering to Global Initiative for Asthma (GINA)
      guidelines. However the use of sputum to measure eosinophil levels is expensive and
      impractical within a clinical setting. This study explores the use of blood-eosinophil
      levels as a clinical predictor for exacerbations and asthma control within a UK primary care
      dataset.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Exacerbations</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as:
American Thoracic Society / European Respiratory Society (ATS/ERS) task force definition: Asthma related hospital admissions OR accident and emergency  (A&amp;E) room attendance OR Use of acute oral steroids
Clinical definition: ATS/ERS definition including any GP consultations for lower respiratory related tract infections (LRTIs) treated with antibiotics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma control</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as:
Risk domain asthma control: No Asthma-related  hospital attendance, A&amp;E attendance, out-patient department attendance, no prescriptions for acute oral steroids and no GP consultations for LRTIs treated with antibiotics
Overall asthma control: Risk domain asthma control definition, including average daily dose of ≤200mcg salbutamol</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">130248</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Blood eosinophil count ≤ 400/µl</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood eosinophil count &gt; 400/µl</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A retrospective database analysis of asthma patients with a valid eosinophil count (where
        valid: numeric value expressed as /µl at least one year prior to last data extraction)
        with at least one year of data of prior to the date of eosinophil count (baseline period)
        and one year of data post recorded eosinophil count (outcome period).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 12-80 at date of last eosinophil count

          -  Asthma diagnosis at any time

          -  Blood Eosinophil reading in patient record (numeric count expressed in µl) at least
             one year prior to last data extraction

          -  Two years of continuous data

        Exclusion Criteria:

          -  Any other chronic respiratory diseases

          -  Eosinophil counts &gt;5000/µl (outliers)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Price, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aberdeen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research in Real Life Ltd</name>
      <address>
        <city>Cambridge</city>
        <zip>CB24 3BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.optimumpatientcare.org/Html_Docs/OPCRD.html</url>
  </link>
  <link>
    <url>http://www.cprd.com/intro.asp</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Blood eosinophils</keyword>
  <keyword>Sputum eosinophils</keyword>
  <keyword>Clinical predictor</keyword>
  <keyword>UK primary care</keyword>
  <keyword>Global Initiative for Asthma (GINA)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
